Bio-Rad Laboratories shares moved higher in a session where investors again emphasized the company’s strategic equity investment in Sartorius AG and the way that holding can dominate Bio-Rad’s reported net income through fair-value (mark-to-market) remeasurement.

Bio-Rad’s filings and earnings materials have repeatedly shown that changes in the fair market value of its Sartorius position can swing quarterly and annual results by hundreds of millions of dollars. In its annual filing, Bio-Rad illustrated that a 10% move in Sartorius’s quoted share prices would translate into an approximate $566.9 million gain or loss recognized in Bio-Rad’s income statement line for changes in fair market value of equity securities and a loan receivable, underscoring how quickly reported profitability can change even without an operational shift. (sec.gov)

Bio-Rad’s latest full-year results reiterated the same core point: the company’s reported bottom line can be heavily influenced by fair-value changes in the Sartorius investment, which materially contributed to net income in 2025. That backdrop can amplify stock moves when investors expect improving conditions for life-science tools/bioprocessing demand and re-rate the value of the stake embedded in BIO. (investors.bio-rad.com)

Investors will be watching for catalysts that clarify the trajectory of the underlying operating business (life science research and clinical diagnostics), as well as any incremental updates tied to the Sartorius investment and its fundamentals, which Bio-Rad has recently provided through selected financial metric updates. (tipranks.com)